PT-141 (Bremelanotide) research and evidence overview

PT-141 (bremelanotide) has the most legible evidence trail of any peptide sold in "research" catalogs: two decades of published human trials culminating in FDA approval as Vyleesi on June 21, 2019 (Drugs@FDA, NDA 210557). The trail has a sharp turn in the middle — a male erectile-dysfunction program that generated real data and was then abandoned — and understanding that turn is the key to reading today's claims about the compound.

The story starts with a side effect. In a 1998 double-blind crossover study of the tanning peptide melanotan-II, 8 of 10 men with psychogenic erectile dysfunction developed clinically apparent erections, with rigidity lasting 38 minutes versus 3 on placebo (Wessells et al., J Urol 1998). PT-141, a melanotan-II derivative, was developed to chase that signal deliberately: it produced erections in rats and nonhuman primates, activated hypothalamic neurons, and caused rapid dose-dependent erectile responses in men (Molinoff et al., Ann N Y Acad Sci 2003).

Two 2004 trials fleshed out the human data. Subcutaneous PT-141 (0.3–10 mg) produced statistically significant erectile responses above 1 mg in healthy men, and at 4–6 mg in patients who had failed sildenafil (Rosen et al., Int J Impot Res 2004). An intranasal formulation was significant above 7 mg, with a half-life around 2 hours (Diamond et al., Int J Impot Res 2004). But the intranasal route showed wide variability in bioavailability — some patients absorbed far more drug than intended, with corresponding blood-pressure elevations — and it was discontinued; development refocused on subcutaneous delivery and a different indication (White et al., J Hypertens 2017). The ED indication was never resumed, which is why "PT-141 for men" rests on 20-year-old early-phase data with no approved dose or safety standard behind it.

The pivotal evidence is RECONNECT: two identical randomized, double-blind, placebo-controlled phase 3 trials (studies 301 and 302) in premenopausal women with acquired, generalized hypoactive sexual desire disorder — 1,267 women randomized to bremelanotide 1.75 mg subcutaneous as needed or placebo for 24 weeks (Kingsberg et al., Obstet Gynecol 2019). Both co-primary endpoints were met:

• FSFI desire domain (scored 1.2–6.0): +0.30 and +0.42 versus placebo in the two trials (integrated +0.35, p<0.001).

• Desire-related distress (FSDS-DAO item 13): −0.37 and −0.29 (integrated −0.33).

• Nausea, flushing, and headache each affected ≥10% of treated women; most events were mild or moderate.

A 52-week open-label extension enrolled 684 completers; improvements were sustained in women continuing treatment (desire-domain gains of ~1.25–1.30 from baseline), no new safety signals emerged, and nausea remained the dominant adverse event at 40.4% (Simon et al., Obstet Gynecol 2019). Read plainly: the effect is consistent and statistically robust, and its average magnitude is modest — a fraction of a point on the desire scale — which is why candid framing matters more for this drug than for most.

The FDA approved bremelanotide injection (Vyleesi, NDA 210557) on June 21, 2019 for acquired, generalized HSDD in premenopausal women (Drugs@FDA); the label explicitly excludes use in men, in postmenopausal women, and for performance enhancement (Vyleesi label). The approval and development history are summarized in the peer-reviewed literature as well (Dhillon & Keam, Drugs 2019). Peptide-catalog "PT-141" sits entirely outside this framework: same molecule on the label of the vial, none of the verification behind it.

• Men — no phase 3 data, no approved dose, no established benefit–risk; the early-phase erectile signals were never carried forward.

• Postmenopausal women — outside the studied population and the label.

• General "libido enhancement" — not a trial endpoint in any completed program; the measured outcomes were desire and distress within a diagnosed disorder.

• Long-term pigmentation — hyperpigmentation risk with years of use, especially at above-label frequency, is not characterized.

• Mechanism — even the label concedes the mechanism in HSDD is unknown; MC4R-mediated central signaling remains the working hypothesis.

For how these findings translate into day-to-day questions, see the benefits overview, the side-effect data, and the main PT-141 page.